ABC25 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients

Brian J. Wilson1,2, Tobias Schatton1,2, Qian Zhan3, Martin Gasser3, Jie Ma1,2, Karim R. Saab1,2, Robin Schanche3, Ana-Maria Waaga-Gasser3, Jason S. Gold4,6, Qin Huang7, George F. Murphy3, Markus H. Frank1,2, and Natasha Y. Frank1,5,8

Abstract

Identification and reversal of treatment resistance mechanisms of clinically refractory tumor cells is critical for successful cancer therapy. Here we show that ATP-binding cassette member B5 (ABC25) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)–based chemoradiation therapy and provide evidence for a functional role of ABC25 in colorectal cancer 5-FU resistance. Examination of human colon and colorectal cancer specimens revealed ABC25 to be expressed only on rare cells within healthy intestinal tissue, whereas clinical colorectal cancers exhibited substantially increased levels of ABC25 expression. Analysis of successive, patient-matched biopsy specimens obtained prior to and following neoadjuvant 5-FU–based chemoradiation therapy in a series of colorectal cancer patients revealed markedly enhanced abundance of ABC25-positive tumor cells when residual disease was detected. Consistent with this finding, the ABC25-expressing tumor cell population was also treatment refractory and exhibited resistance to 5-FU–induced apoptosis in a colorectal cancer xenograft model of 5-FU monotherapy. Mechanistically, short hairpin RNA–mediated ABC25 knockdown significantly inhibited tumorigenic xenograft growth and sensitized colorectal cancer cells to 5-FU–induced cell killing. Our results identify ABC25 as a novel molecular marker of therapy-refractory tumor cells in colorectal cancer patients and point to a need for consistent eradication of ABC25-positive resistant tumor cell populations for more effective colorectal cancer therapy. Cancer Res; 71(15): 5307–16. ©2011 AACR.

Introduction

Colorectal cancer is a leading cause of cancer-related mortality. It arises from the accumulation of genetic mutations in normal epithelium, leading to the development of adenomas with eventual neoplastic transformation into invasive, metastatic carcinomas (1). Despite significant progress in early detection and treatment of colorectal cancer, a high proportion of patients with surgically resectable tumors eventually succumb to metastatic disease originating from residual microscopic malignancy, not evident at the time of surgery (1, 2). Adjuvant therapeutic modalities such as radiotherapy and chemotherapy are designed to target residual tumor cells; however, their success is currently limited by the existence of therapy-resistant cancer cell populations (2–4).

Fluorouracil (5-FU) is one of the main chemotherapeutic agents for colorectal cancer. In patients with advanced colorectal cancer, treatment with 5-FU reduces tumor size by approximately 50% and prolongs median survival by 5 months (5). Identification and targeting of 5-FU–resistant populations might, therefore, be expected to lead to further improvements in advanced colorectal cancer survival.

Recent studies have revealed heterogeneity of human colorectal cancers with regard to molecular markers that identify highly tumorigenic and potentially therapy-resistant cancer subpopulations, including CD133, ESA10, ALDH1, WNT (6–10). For example, in vitro treatment of human HT-29 colorectal cancer cells with high doses of 5-FU resulted in significant enrichment of CD133+ colorectal cancer subpopulations (11) and CD133+ colorectal cancer cells can be sensitized to 5-FU- or oxaliplatin-mediated cell killing by using an anti-IL-4 neutralizing antibody (12) or specific gene silencing of the aurora-A kinase (13). In addition, CD133-overexpressing tumors were...
found to be more resistant to 5-FU–based chemotherapy and CD133 expression was associated with poor prognosis in a recent study of 501 cases of human colorectal cancer (14). Although additional studies are required to further delineate whether all heterogeneously expressed colorectal cancer markers (6–10, 15) identify hierarchical tumor organization, as posited by the cancer stem cell model (16), and while more work is necessary to define their specific relationships, the data to date suggest preferential survival of CD133+ colorectal cancer cells following chemotherapy and underline the importance of identifying and, ultimately, targeting all possible resistance mechanisms of these aggressive tumor subpopulations (2, 3).

We have recently cloned and characterized ABCB5 [ATP-binding cassette, sub-family B (MDR/TAP), member 5; refs. 17–22], a chemoresistance gene in human melanomas (18, 23, 24) and hepatocellular carcinomas (25) preferentially expressed on CD133+ tumor cells (18, 25), which correlates with clinical tumor progression in these malignancies according to results from several laboratories (19, 25–27) and serves as a major independent biomarker of tumor recurrence and poor survival in human hepatocellular carcinoma patients (25). Our previous analysis of mRNA expression across diverse physiologic and malignant human tissues showed that ABCB5 is also expressed in human colorectal cancer (18). Therefore, we hypothesized that ABCB5 might identify therapy-refractory tumor populations in patients with colorectal cancer and that ABCB5, similar to its role in melanoma (23), might contribute to 5-FU resistance in this malignancy. Our results identify ABCB5 overexpression in clinical colorectal cancers compared with healthy controls and show that ABCB5 marks therapy-refractory tumor subpopulations following neoadjuvant 5-FU–based chemoradiation treatment in colorectal cancer patients. Mechanistically, utilization of a colorectal cancer xenotransplantation model reveals resistance of ABCB5+ tumor subpopulations to 5-FU–induced apoptosis. Moreover, stable short hairpin RNA (shRNA)-mediated ABCB5 knockdown in human colorectal cancer cells enhances 5-FU–mediated cell killing.

Materials and Methods

Clinical colorectal cancer specimens

Clinical colorectal tumor specimens were obtained from patients according to human subjects research protocols approved by institutional IRBs at the VA Boston Healthcare System and the University of Würzburg Medical School. Baseline ABCB5 expression was examined in tumors of diverse stages resected from 15 patients not subjected to preoperative treatment (Supplementary Table S1). In addition, patient-matched biopsy specimens derived from 7 rectal cancer patients prior to and following neoadjuvant treatment with chemoradiation (bolus 5-FU treatment and long-course 40–52 Gy total dose radiotherapy) and subsequent curative surgical resection were included in the study (Supplementary Table S2) for analysis of ABCB5 expression in pretreatment tumor biopsies and posttreatment surgically resected tumors.

Colorectal cancer cells and culture methods

Authenticated human colorectal cancer cell lines (HT-29 and SW-480) were obtained from American Type Culture Collection and were cultured and passaged for fewer than 6 months in RPMI 1640 medium (Lonza Bio-Whittaker) supplemented with 10% (v/v) FBS (Invitrogen GIBCO) and 1% (v/v) penicillin/streptomycin (Lonza Bio-Whittaker). COLO205, HCT-116, HCT-15, HT-29, HCC-2998, KM12, and SW620 mRNA specimens were provided by the NCI/NIH Developmental Therapeutics Program.

Antibodies

The anti-ABCB5 monoclonal antibody (mAb) 3C2-ID12 (17–19), commercially available from AbD Serotec, was used for flow cytometric and immunohistochemical analyses. Unconjugated MOPC-31C mouse isotype control mAb was purchased from BD Pharmingen and APC-conjugated secondary Ab from eBioscience. For Western blots, the following polyclonal Abs (pAbs) were used: rabbit anti-human ABCB5 (Abgent), rabbit anti-human α-Tubulin (Abcam), and horse-radish peroxidase (HRP)-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch). The following Abs were used for immunohistochemistry or immunofluorescence staining: Rabbit anti-CD133 (Abcam), alkaline phosphatase horse anti-mouse or goat anti-rabbit IgG, peroxidase goat anti-rabbit IgG, Alexa Fluor 594 donkey anti-rabbit IgG, and Alexa Fluor 488 donkey anti-mouse IgG (Invitrogen).

Histopathology and immunohistochemistry

For single-label immunohistochemistry, 5-μm sections were deparaffinized in xylene 2 × 10 minutes, followed with 2 × 100% ethanol, 95% and 75% ethanol, 3 × dH2O, 2 minutes for each. Subsequently, sections were placed in 1× target retrieval solution (Dako) and boiled in a Pascal pressure chamber (Dako) at 125°C for 30 seconds, 90°C for 10 seconds and were then allowed to cool to room temperature. Immunohistochemistry was done as described previously (19, 22). Briefly, the sections were incubated with primary Ab at 4°C overnight. After washing out unbound primary Ab with TBST-0.05% tween 20 (TBST), the tissue sections were incubated with peroxidase-conjugated or alkaline phosphatase (AP)-conjugated secondary Ab at room temperature for 30 minutes, then washed with TBST 3 × 5 minutes. Immunoreactivity was detected by using NovaRED peroxidase substrate or AP red substrate (Vector Laboratories). For double-label immunohistochemistry, sections were deparaffinized and heat-induced antigen retrieval with Target Retrieval Solution (Dako) was used. Sections were incubated with ABCB5 mAb and CD133 mAb at 4°C overnight and then with peroxidase-conjugated horse anti-rabbit Ab (Vector) and AP-conjugated horse anti-mouse Ab at room temperature for 30 minutes. CD133 staining was detected with NovaRED peroxidase substrate and ABCB5 staining was detected with AP red substrate (Vector Laboratories). For double-label immunofluorescence, sections were deparaffinized and heat-induced antigen retrieval with Target Retrieval Solution (Dako) was used. Slides were blocked for 30 minutes with serum, incubated with ABCB5 mAb and CD133 mAb at 4°C overnight and then incubated...
with the appropriate secondary Abs in the dark for 1 hour. After washing out secondary Ab, slides were then coverslipped with ProLong Gold Anti-Fade with DAPI (4',6-diamidino-2-phenylindole; Invitrogen). Sections were analyzed with a BX51/BX52 microscope (Olympus America Inc.). Images were captured by using the CytoVision 3.6 software (Applied Imaging). For quantitative analysis of ABCB5 expression, ImageJ software (http://rsbweb.nih.gov/ij/), which calculates percentage pixel area, coupled with the Color Deconvolution plug-in (http://www.dentistry.bham.ac.uk/landingham/software/cdeconv/cdeconv.html), was used to quantify the percentage of tissue that showed immunoreactivity for ABCB5 in microscopically acquired JPEG images of normal colon, clinical colorectal cancers, and 5-FU–treated cancer xenografts. Measurements of ABCB5 expression in normal colon were done in clinically and histologically uninvolved portions of surgical specimens of the same group of colorectal cancer patients (Supplementary Table S1). ABCB5 staining intensity in full thickness colonic wall specimens was hereby evaluated in histologically selected areas representing only colonic epithelium to avoid inclusion of nonepithelial stromal, submucosal, and muscular elements. In each case, ImageJ analysis software was used to quantify the pixel intensity of the selected areas as described previously (28).

Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling/ABCB5 costaining

The ApopTag TdT Enzyme Kit (Chemicon International) was used for terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling (TUNEL) staining. After deparaffinization and antigen retrieval, the colorectal cancer sections were incubated with TdT enzyme mixture with 77 mL ApopTag reaction buffer with 33 mL ApopTag TdT Enzyme (33 mL of H2O instead of TdT enzyme was used as a negative control) at 37°C for 1 hour and then washed with H2O and PBS once for each assay. The sections were incubated with ABCB5 mAb at 4°C overnight and then with peroxidase-conjugated sheep anti-DIG Ab (Roche) and AP-conjugated horse anti-mouse Ab at room temperature for 30 minutes. TUNEL staining was detected with NovaRED peroxidase substrate (Vector) and ABCB5 staining was detected with AP NBT/BCIP.

Flow cytometry

Cells were harvested by using Versene (Invitrogen) as described (17, 18) and dissociated HT-29 and SW480 cell cultures were passed through a 40-μm nylon mesh to exclude cell aggregates followed by trypan blue examination for cell viability, as described previously (29, 30). Single cell suspensions used for flow cytometry consistently showed more than 99% cell viability (trypan blue exclusion) and absence of cell detritus or cell clusters. Analysis of ABCB5 expression in HT-29 and SW480 colon cancer cells was done by single-color flow cytometry as described previously (18, 19). Briefly, 1 x 10^6 cells were incubated for 30 minutes at 4°C with APC-conjugated anti-ABCB5 mAb or APC-conjugated isotype control mAb (10 μg/mL), and single-color flow cytometry was subsequently carried out on un gated cells with acquisition of fluorescence emission at the FL4 (APC) spectrum on a Becton Dickinson FACScan (Becton Dickinson). The positive gates were set at a detection threshold of 0.1% of cells in control mAb-stained samples.

Real-time quantitative reverse transcription-PCR

Total RNA was prepared from all 7 of the NCI-60 colorectal cancer cell cultures maintained at the National Cancer Institute and real-time quantitative reverse transcription-PCR (qRT-PCR) was done as described previously (18). The primers for ABCB5 [Homo sapiens ATP-binding cassette, sub-family B (MDR/TAP), member 5 (ABCB5), transcript variant 2, mRNA NCBI Reference Sequence: NM_178559.5] detection were 5’-CACAAAAGGCCATTCAAGCT-3’ (forward) and 5’-GCTGAG-GAATCCACCCATCT-3’ (reverse) and the primers for β-actin were 5’-CCTGGCACCCAGCAACT-3’ and 5’-GCCGATCC-CACGGATGACT-3’ (18). Relative gene expression was measured with the GeneAmp 7000 Sequence Detection System (Applied Biosystems) and ABCB5 expression was assessed by the ratio of the expression level in the sample against mean expression in all samples as described previously (18).

Full ABCB5 mRNA open reading frame identification in HT-29 and SW480 colorectal cancer cells

RNA was prepared by using RNeasy Mini Kit (Qiagen) and reverse-transcribed by using the Advantage RT-for-PCR Kit (Clontech) according to the manufacturers’ instructions. cDNA was then subjected to PCR amplification of the full ABCB5 open reading frame (ORF; transcript variant 2, mRNA NCBI Reference Sequence: NM_178559.5) as previously described for human melanocytes (17). For sequencing reactions, the PCR product was then used as a template for nested PCR of 3 overlapping fragments encompassing the ORF. N-terminal: Forward (ATGGTGGATGAGATGACTCATGAGACTTCTTCCTACATGCAAGAACCCTC), reverse (GAATTAATAGGCTCCTAAATCGAACCCTC); Middle: Forward (AAATGCTGATTTGGTCACAAAGAAGATACGC), reverse (TTCTCAGGGAGACCTTCAATATAAAAAGAATG); C-terminal: Forward (AAATAG AAATCAGTGTTCCTCAGAAGGCTTCTG), reverse (TCATGCTGACTGTCCTGTTCAACTACACTACT). The full ORF sequences of ABCB5 (transcript variant 2, mRNA NCBI Reference Sequence: NM_178559.5) expressed by the human HT-29 and SW480 colorectal cancer cell lines were submitted to the GenBank database under the following accession numbers: GU437216 for HT-29, and GU437217 for SW480.

Animals

Nonobese diabetic/severe combined immunodeficient mice (NOD/SCID) and NOD/SCID interleukin-2 (IL-2) Rγc−/− mice were purchased from the Jackson Laboratory. The human colorectal cancer to NOD/SCID mouse xenotransplantation model was used to dissect colorectal cancer drug resistance, because it represents an established model system (6, 7). NOD/SCID IL-2Rγc−/− (NSG) mice, which have a higher tumor take for some cancers because of more profound host immune suppression (22), were selected as the model of choice to assess intrinsic molecular function of ABCB5, independent of potential tumor microenvironmental interactions (22). Mice...
were maintained in accordance with the institutional guidelines of Children's Hospital Boston and Harvard Medical School and experiments were done according to approved experimental protocols.

**Human colorectal cancer xenotransplantation and 5-FU treatment**

HT-29 or SW480 human colorectal cancer cells (1 × 10^6 each) were injected s.c. into the right flanks of recipient NOD/SCID mice. Tumor formation was assayed weekly and tumor volumes were calculated as described previously (19). At 5 weeks (HT-29) or 9 weeks (SW480) posttumor cell inoculation, mice were randomized into 5-FU (Teva) or vehicle control treatment groups with similar tumor volumes. 5-FU was administered by daily intraperitoneal injection for 5 consecutive days, as described (31, 32), at 50 mg/kg body weight, and control animals were given PBS at equal volumes. Tumor xenografts were harvested 1 day following administration of the final treatment dose, and frozen or paraffin-embedded colon cancer sections were prepared for subsequent immunohistochemical analysis. In addition experiments, HT-29 or SW480 human colorectal cancer cells, or their corresponding stable ABCB5 shRNA knockdown or vector control variants (1 × 10^6 cells/mouse, respectively) were injected s.c. into the right flanks of recipient NOD/SCID IL-2Rγ−/− mice. Tumorigenic growth of untreated HT-29 or SW480 human colorectal cancer cells or their corresponding stable ABCB5 shRNA knockdown or vector control variants were assayed weekly as a time course, at least up to the endpoint of 7 weeks, unless excessive tumor size or disease state required protocol-stipulated euthanasia earlier, by determination of tumor volume as described previously (19).

**Generation of stable ABCB5 knockdown colorectal cancer cell variants**

Generation of stable HT-29-pSUPER-Retro-Puro-ABC5, SW480-pSUPER-Retro-Puro-ABC5, or their respective empty vector cell variants was accomplished by transfection of plasmids with FuGENE 6 Transfection Reagent followed by puroycin selection (1 μg/mL and 2 μg/mL, respectively). The ABCB5 shRNA target sequence GCTGGAAAGATAGCAACTGTTGCTGTA was as previously described (24). Knockdown was confirmed by RT-PCR amplification by using ABCB5-specific primers and 35 cycles of amplification and comparison relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RT-PCR amplification from the corresponding samples, with 28 cycles of the primers. The primers were as follows: ABCB5: Forward (GCGAGCAAAGGTCGGACTACAATCGTGG), reverse (CCCGAACACAAAGGGCCATTCAGGC); GAPDH: Forward (ACACAGTCCATGGCCATCAC), reverse (TCCACCCCTCGTTGCTGTA). Confirmation of ABCB5 knockdown at the protein level was done by utilizing an immunoprecipitation (IP)-Western blot by using a rabbit anti-ABC5 pAb. Briefly, 1 mg (HT-29) or 4 mg (SW480) total cell lysate and their respective knockdown lysates were sonicated and precleared before incubation with 2 μg ABC5 Ab with protein G agarose for 3 hours at 4°C. IPs were then washed 4× before SDS-PAGE and Western blot. The buffer used for lysis and IP was 50 mmol/L Tris pH 7.5, 1% NP-40, 0.1% SDS, 150 mmol/L NaCl, 0.5 mmol/L EDTA, 1 mmol/L DTT, 1 × complete protease inhibitor cocktail (Roche). A tubulin Western blot was used as a control for lysate concentrations.

**MTT cell growth and cytotoxicity assays**

*In vitro* growth kinetics of HT-29 or SW480 human colorectal cancer cells or their corresponding stable ABCB5 shRNA knockdown or vector control variants were assayed by using the MTT cell proliferation assay as described previously (18). To determine the effect of ABCB5 gene knockdown on 5-FU–induced cell killing, cells were seeded in 96-well dishes and exposed to a range of 5-FU concentrations (0.5–100 mmol/L) and the dose response of cell viability was measured after 7 days of drug treatment by using a TACS MTT Cell Proliferation Assay Kit (Trevigen) according to the manufacturer’s protocol, as previously described for doxorubicin in human melanoma cells (18).

**Statistical analysis**

Statistical differences between expression levels of markers, between surviving cell fractions, or between tumor volumes were determined by using the nonparametric Mann–Whitney test, with 2-sided P values of P < 0.05 considered significant. Pearson correlation coefficients were calculated for assessment of ABCB5 expression–drug potency relationships. The dual criteria of P < 0.05 and r > 0.3 were used to identify significant negative correlations as described previously (18).

**Results**

**ABCB5 is expressed only on rare cells in healthy colonic mucosa but markedly increased in human colorectal cancer**

In healthy human colon, we found ABCB5 to be expressed only on rare, distinct cells residing preferentially at or near the base of colonic crypts (Fig. 1A), which also contain CD133-positive cells (Fig. 1A). Furthermore, ABCB5-positive crypt cells coexpressed CD133, a candidate marker of intestinal stem cells (33, 34) and this cell population represented a subset of the CD133-expressing component (Fig. 1B). Interestingly, ABCB5 and CD133 were expressed on opposite poles of individual cells, in keeping with the phenomenon of apico-basal polarity attributed to normal columnar epithelial cells (35). In clinical human colorectal cancer specimens, ABCB5 could also be detected to coexpress CD133, a marker of 5-FU–resistant tumor populations in colorectal cancer (14, 36) and a candidate marker of more aggressive colorectal cancer cells according to some reports (7, 8), in the same tumor regions and on the same cancer cells (Fig. 1C). Intriguingly, ABCB5 was expressed at higher levels in lesser differentiated areas of human colorectal cancer specimens compared with better differentiated areas (Fig. 1D, left panels), based on conventional histopathologic evaluation of the correlative architecture and cytology of individual patient samples (37), similar to previous observations in malignant melanoma in which ABCB5 expression was found to correlate with more advanced stages of disease (19, 26). Aggregate
quantitative analysis of all tissue specimens examined (Supplementary Table S1) showed marked ABCB5 overexpression in colorectal cancer specimens compared with normal colonic mucosa (ABCB5 positivity 15.39% ± 4.06% vs. 0.66% ± 0.24% of cells, respectively; mean ± SEM, P = 0.0016; Fig. 1D, right panel). These results provide initial evidence that the chemoresistance mediator ABCB5 is overexpressed in human colorectal cancer.

**ABCB5**

**colorectal cancer cells exhibit increased resistance to 5-FU therapy**

On the basis of previously shown functions of ABCB5 as a chemoresistance mediator in human melanoma (18, 23, 24) and hepatocellular carcinoma (25), and on the here-identified preferential coexpression of ABCB5 with CD133, a marker of 5-FU-resistant tumor populations in colorectal cancer (14, 36), we investigated ABCB5 expression prior to and following standard 5-FU-based neoadjuvant chemoradiation therapy in a series of human rectal cancer patients (Supplementary Table S2). Analysis of matched diagnostic rectal cancer biopsy specimens in a series of patients who underwent neoadjuvant treatment prior to curative surgical tumor resection revealed ABCB5 positivity in only 5.7% ± 4.6% of rectal cancer cells (mean ± SEM) in pretreatment specimens (Fig. 2A and B), whereas posttreatment specimens showed markedly increased levels of ABCB5 expression (P < 0.01), with 32.3% ± 8.8% of cancer cells staining positively for ABCB5 (Fig. 2A and B). Posttreatment rectal cancer specimens also revealed preferential coexpression of ABCB5 with CD133, in the same tumor regions and on the same cancer cells (Fig. 2C). These findings show that **ABCB5** rectal cancer cells are more resistant to neoadjuvant chemoradiation therapy involving 5-FU.

To further dissect a potential role of ABCB5 in colorectal cancer 5-FU resistance, we examined ABCB5 expression and 5-FU treatment response of ABCB5 rectal cancer cell populations in an established *in vivo* model system utilizing NOD/SCID murine recipients of human colorectal cancer xenografts (6, 7). First, we found that ABCB5 expression levels correlated significantly with colorectal cancer resistance to 5-FU (Pearson correlation r = 0.531, P = 0.019; Fig. 3A) when ABCB5 mRNA expression was determined by qRT-PCR analyses in 7 colorectal cancer lines from the NCI-60 panel used by the National Cancer Institute for drug screening and compared with the respective 5-FU GI50 values available from the NCI Developmental Therapeutics Program (18). SW480 and

Figure 1. ABCB5 expression in physiologic colon and colorectal cancer. A, representative immunohistochemical analysis of ABCB5 protein expression (AP, red, left 2 panels) or CD133 expression (third panel) in physiologic human colon tissue compared with isotype control staining (right). Arrows demarcate cells expressing ABCB5 and CD133 in sections of full-length crypts from the luminal surface of the colon to the crypt bases bordered by underlying connective tissue. B, representative ABCB5/CD133 coexpression in human colon crypt cells showing basilar staining for ABCB5 (AP, red) and apical staining for CD133 (HRP, brown) in both a cross and lateral section.
HT-29 cells were selected for further study on the basis of their well-characterized in vivo tumorigenic potential and were found to express the principal ABCB5 mRNA isoform first identified in human malignant melanoma (ref. 17; NCBI Reference Sequence: NP_848654.3), as determined by RT-PCR amplification, cloning, and sequencing of the corresponding complete 2,784-bp cDNA ORF (deposited to the GenBank database under accession numbers GU437217 and GU437216, respectively; Fig. 3B, left panel). ABCB5 protein expression by SW480 and HT-29 cells was shown by flow cytometry (Fig. 3B, left panel), ABCB5 protein expression by SW480 and HT-29 cells was shown by flow cytometry (Fig. 3B, right panels) and IP and Western blotting (Fig. 4A), with 20.1% of SW480 and 4.9% of HT-29 colorectal cancer cells found to express ABCB5 (Fig. 3B, right panels). In vivo, quantitative immunohistochemical expression analyses of HT-29 or SW480 tumor xenograft specimens resected from 5-FU–treated or vehicle control–treated NOD/SCID recipient mice showed that 38.8% / C6 5.8% of cancer cells in tumors of 5-FU–treated xenograft recipients expressed ABCB5, a significantly increased proportion compared with 18.4% / C6 3.6% ABCB5 positivity in tumors derived from vehicle control–treated xenograft recipients (mean / C6 SEM, P = 0.011; Fig. 3C and D). ABCB5/TUNEL double staining of tumor specimens derived from 5-FU–treated xenograft recipients revealed enhanced resistance to 5-FU–induced apoptotic cell killing of ABCB5+ cells (predominantly TUNEL-negative) compared with ABCB5− cells (predominantly TUNEL positive) following systemic 5-FU therapy (Fig. 3C). In aggregate, these results reveal increased therapeutic resistance of ABCB5+ colorectal cancer cells, compared with ABCB5− tumor populations, to 5-FU treatment.

ABCB5 mediates 5-FU resistance in human colorectal cancer cells

The findings of increased resistance of ABCB5+ colorectal cancer cells to 5-FU therapy suggested that ABCB5 might functionally contribute to 5-FU resistance in this malignancy, similar to the role of a related ABCB5 isoform (NCBI Reference Sequence: NM_001163942.1) in human melanoma (23). To explore the potential role of ABCB5 as a 5-FU resistance mediator in colorectal cancer, we generated stable ABCB5 shRNA knockdown (ABCB5-KD) or pSUPER vector control variants for both SW480 and HT-29 colorectal cancer cells. Significant ABCB5 knockdown was shown for both HT-29 and SW480 cells (Fig. 4A) at both the mRNA level by using RT-PCR.
NS; culture doubling time SW480ABCB5-KD vs. SW480control: 17.9 with significant reductions of the LD50 for both HT-29ABCB5-KD concentrations greater than 5 nmol/L in both HT-29 and SW480 cells, as low as 0.5 nmol/L in HT-29 cells, and at all 5-FU concentrations, significant enhancement of cell killing at 5-FU concentrations in HT-29 and SW480 colorectal cancer cells (Fig. 4D), resulting in knockdown significantly reversed the 5-FU resistance of both HT-29ABCB5-KD or SW480ABCB5-KD colorectal cancer cells (Fig. 4B), even upon long-term, 3-week in vitro culture (Fig. 4A). First, in vitro and in vivo growth characterization of ABCB5 knockdown variants versus controls revealed that in vitro proliferation was not significantly different for HT-29ABCB5-KD versus HT-29control or SW480ABCB5-KD versus SW480control cells (Fig. 4B), even upon long-term, 3-week in vitro culture (culture doubling time HT-29ABCB5-KD vs. HT-29control: 18.7 ± 1.8 hours vs. 17.9 ± 1.4 hours, mean ± SD, NS; culture doubling time SW480ABCB5-KD vs. SW480control: 17.9 ± 0.8 hours vs. 18.0 ± 0.2 hours, mean ± SD, NS). In contrast, in vivo tumorigenic growth resulting from xenotransplantation of HT-29ABCB5-KD or SW480ABCB5-KD cells was significantly inhibited compared with that resulting from xenotransplantation of HT-29control or SW480control cells, respectively (HT-29ABCB5-KD vs. HT-29control at 7 weeks: 336 ± 23 mm³, 71% inhibition, P = 0.0163; SW480ABCB5-KD vs. SW480control at 5 weeks: 429 ± 23 mm³ vs. 983 ± 108 mm³, 66% inhibition, P = 0.001; Fig. 4C), pointing to a functional role of ABCB5 in tumorigenic growth. Next, on the basis of identical growth characteristics of untreated control and ABCB5-KD colorectal cancer cells in vitro, we subjected ABCB5-KD or control cells to 5-FU–induced cell killing as a dose response to increasing 5-FU concentrations in 1-week drug exposure assays, followed by cell viability measurements to assess relative cell death, using an MTT assay (18). ABCB5 knockdown significantly reversed the 5-FU resistance of both HT-29 and SW480 colorectal cancer cells (Fig. 4D), resulting in significant enhancement of cell killing at 5-FU concentrations as low as 0.5 nmol/L in HT-29 cells, and at all 5-FU concentrations greater than 5 nmol/L in both HT-29 and SW480 cells, with significant reductions of the LD50 for both HT-29ABCB5-KD vs. HT-29control cells (LD50 2.6 nmol/L vs. 12 nmol/L, respectively, 4.6-fold sensitization, P < 0.0001) and SW480ABCB5-KD vs. SW480control cells (LD50 2.6 nmol/L vs. 22 nmol/L, respectively, 8.5-fold sensitization, P < 0.0001). These results show that ABCB5 mediates 5-FU resistance in human colorectal cancer cells.

Discussion

In this study, on the basis of our previous identification of ABCB5 mRNA expression in human colorectal cancer (18), we carried out an in-depth analysis of ABCB5 expression and function involving healthy human colon specimens from 9 distinct individuals, colorectal cancer specimens from 23 patients, and 8 established colorectal cancer cell lines. First, we found ABCB5 expression to be restricted to rare cells within the healthy human colon but detected marked overexpression in human colorectal cancer. These results identify ABCB5 expression in clinical human colorectal cancer and parallel findings in melanoma and hepatocellular carcinoma of absent or rare ABCB5 expression in the respective nonmalignant tissues, but overexpression in the corresponding malignancies (19, 25–27). Intriguingly, we found ABCB5 to be coexpressed with CD133 on the same individual cells in healthy colon and in human colorectal cancer, also resembling previous findings of coexpression of these molecular markers in human skin and malignant melanoma (17–19) and hepatocellular carcinoma (25). Because CD133 represents a candidate intestinal stem cell marker (34) and potential marker of colorectal cancer stem cells (7, 8), and because colorectal cancers can originate from physiologic intestinal stem cells (34, 38) including CD133+ colon crypt populations (34), ABCB5 might provide a novel molecular link between the physiologic colonic stem cell niche and the cell-of-origin for colon cancer.
Second, our results reveal that ABCB5^+ malignant subpopulations are resistant to 5-FU–based chemoradiation therapy in rectal cancer patients, thereby establishing ABCB5 as a novel molecular marker of clinically therapy-refractory colorectal cancer cells. The preferential coexpression of CD133 by 5-FU–resistant ABCB5^+ cancer cells is consistent with previous findings that documented increased CD133 expression among 5-FU–resistant colorectal cancer cell subsets in vitro (11), and clinical findings of increased resistance of CD133^+ colorectal tumors to 5-FU–based chemotheraphy in human patients (14). In addition, our results show that ABCB5^+ malignant subpopulations are also resistant to clinical radiation therapy. Importantly, although a functional role in cancer therapeutic resistance has not been attributed to date to CD133, ABCB5 isoforms have been shown to confer resistance to multiple chemotherapeutic agents in malignant melanoma and hepatocellular carcinoma (18, 23–25). Our findings therefore establish a novel link between biomarkers of therapeutic resistance and a molecular drug resistance mechanism in clinical colorectal cancer.

Finally, the observed expression of the drug resistance mediator ABCB5 by 5-FU–refractory colorectal cancer cell populations suggested a potential functional role of ABCB5 as a mediator of 5-FU resistance in colorectal cancer. Emergence of 5-FU resistance is a major impediment to successful colorectal cancer therapy, but the various potential mechanisms of 5-FU resistance in this malignancy, particularly of more aggressive and resistant CD133^+ cancer subpopulations that correlate with recurrence and poor prognosis (14, 36, 39), have not been fully explored. Our results provide initial evidence for...
a functional contribution of ABCB5 to 5-FU resistance in human colorectal cancer, because stable shRNA-mediated ABCB5 knockdown significantly sensitized human colorectal cancer cells to 5-FU-induced cell killing. Thus, therapy-refractory colorectal cancer cells that might cause tumor recurrence possess a protective mechanism, ABCB5, potentially intrinsic to CD133+ populations from which the tumor arises (7, 8, 34). This function parallels the roles of additional ABC transporters in cancer drug resistance, including of ABCB1 and ABCG2, which afford protection to normal stem cells and cancer cell subsets in the corresponding malignancies in other tissues (40). Our results therefore suggest a novel molecular link between clinical drug resistance and potential tumor-initiating cells in human colorectal cancer.

In aggregate, our results identify ABCB5 as a novel molecular marker of therapy-refractory tumor cell population in colorectal cancer patients and point to a need for consistent eradication of ABCB5-positive resistant tumor cell populations for more effective colorectal cancer therapy. ABCB5-targeted resistance reversal or ABCB5-positive cancer cell ablation might therefore represent novel, clinically relevant strategies to ultimately enhance tumor eradication in colorectal cancer patients, to produce more durable clinical responses than those obtained by therapeutic strategies directed predominantly at the bulk population of tumor cells.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Grant Support

This work was supported by funds provided by the NIH/NCI (grants 1R01CA113796 and 1R01CA138231 to M.H. Frank) and the U.S. Department of Veterans Affairs (BLR&D VA CDA 2 Award to J.S. Gold and BLR&D VA Merit Award 10688354 to N.Y. Frank).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 19, 2011; revised May 11, 2011; accepted June 1, 2011; published OnlineFirst June 7, 2011.

References


ABCB5 Identifies a Therapy-Refractory Tumor Cell Population in Colorectal Cancer Patients

Brian J. Wilson, Tobias Schatton, Qian Zhan, et al.

Cancer Res 2011;71:5307-5316. Published OnlineFirst June 7, 2011.

Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-11-0221

Supplementary Material  Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2011/06/07/0008-5472.CAN-11-0221.DC1

Cited articles  This article cites 39 articles, 14 of which you can access for free at: http://cancerres.aacrjournals.org/content/71/15/5307.full.html#ref-list-1

Citing articles  This article has been cited by 1 HighWire-hosted articles. Access the articles at: /content/71/15/5307.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.